Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.

Atorvastatin is a medication that inhibits the HMG-CoA reductase enzyme. Hanmi Pharmaceutical Co., Ltd approved it in January 2008.

Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Trazodone, a selective inhibitor of serotonin reuptake transporter 5, has been a key treatment for depression since its approval in Dec 1981 by Angelini Pharma.

Acetaminophen, a small molecule COX enzyme inhibitor drug approved in January 1966, is widely used for pain relief and fever reduction.

Locus Biosciences has disclosed receiving a $23.9 million investment from BARDA, intended to back the inaugural Phase 2 study of its groundbreaking CRISPR-crafted phage treatment.

Metronidazole, a small molecule drug approved in 1960 by Pfizer Inc., inhibits DNA synthesis and is highly effective against anaerobic bacteria and protozoa.

Onward Therapeutics has begun recruiting for an initial phase clinical study of their innovative dual-targeted antibody, OT-A201, which engages with two distinct immune control points.

Pantoprazole is a small molecule medicine classed as a proton pump inhibitor, which means it reduces the amount of acid generated in the stomach.

Ivermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity.

PharmAbcine Initiates Dosing in Early-Stage Study for PMC-309 with KEYTRUDA (pembrolizumab) in Subjects Facing Severe Solid Cancers.

Prednisone is a widely-used corticosteroid drug for treating inflammatory conditions such as allergies, arthritis, and asthma, working by suppressing the immune system to reduce inflammation.